Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2018-05-22 Investor Presentation
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Presentation on Atopic Dermatitis Market 28 pages 825.2KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation released as an ASX/Media Release dated 23 May 2018. It focuses on a presentation to an Advisory Board regarding the atopic dermatitis market opportunity and the company's clinical development programs. The content includes market analysis, disease overview, clinical pipeline updates, and strategic positioning of the company's products. It is structured as a presentation with slides and detailed commentary, typical of an investor or advisory board presentation. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is not a brief factsheet or a voting result announcement. The document is clearly a presentation aimed at investors and advisors, focusing on financials, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-05-22 English
BOT Presents BTX 1503 Data at International Dermatology Meet 3 pages 133.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 18 May 2018 from Botanix Pharmaceuticals. It announces the presentation of Phase 1b clinical trial data for BTX 1503 at an international dermatology meeting. The content focuses on clinical trial progress, study results, and upcoming Phase 2 trial plans. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about clinical development and capital raising status, not a financial report or regulatory filing. It fits best as a Capital/Financing Update (CAP) because it includes information about the successful capital raising in February 2018 that funds the Phase 2 trial and updates on clinical trial progress relevant to investors and financing activities.
2018-05-17 English
Results of Meeting 2 pages 394.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX/Media Release dated 11 May 2018 reporting the results of a General Meeting. It details the resolutions passed, the votes for and against, proxies, and abstentions. The content focuses on the official announcement of voting outcomes at a shareholder meeting, not the meeting materials themselves or the full annual report. The document length is short (2547 characters) and it explicitly states the results of the General Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-05-10 English
Appendix 3B and Notice Under Section 708A 12 pages 171.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including number of securities issued, issue price, terms, and compliance with ASX listing rules. It includes sections on placement capacity calculations under ASX rules 7.1 and 7.1A, shareholder approvals, and quotation agreements. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities by Botanix Pharmaceuticals Limited. It is not a financial report, earnings release, or management discussion, but a regulatory filing specifically for announcing new share issues and related details. This matches the definition of 'Share Issue/Capital Change' filings (Code: SHA). The document length is substantial (15,000 characters), and it contains the full announcement details, not just a notice or link to a report, so it is not an RPA or RNS. Therefore, the correct classification is SHA with high confidence.
2018-05-08 English
FDA Green Light for BTX 1503 Phase 2 Study 3 pages 115.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 8 May 2018 announcing FDA approval for the IND application for BTX 1503, allowing the company to proceed with a Phase 2 clinical trial. It contains no financial statements or detailed financial data, but rather a corporate update on clinical trial progress and regulatory approval. The content is typical of a Capital/Financing Update or a general corporate announcement related to clinical development milestones. It is not an Annual Report, Earnings Release, or any detailed financial report. It is also not a regulatory filing or report publication announcement since it contains substantive information about the company's progress and plans. Therefore, the best fitting category is Capital/Financing Update (CAP).
2018-05-07 English
Change of Director's Interest Notice * 4 8 pages 155.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including acquisitions and disposals of shares and options. The content is focused on personal share transactions by directors, including dates, number of securities before and after changes, and nature of transactions (off-market acquisitions or disposals). There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing specifically reporting insider trades by directors, which matches the definition of Director's Dealing (DIRS). The document length is substantial and contains detailed transaction data, confirming it is not a brief announcement or certification. Therefore, the correct classification is Director's Dealing (DIRS).
2018-04-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.